HELP REDUCE REDNESS.
less red and more you.

RHOFADE® (oxymetazoline HCI) Cream, 1%

Once-a-day RHOFADE® cream treats the persistent facial redness caused by rosacea so you're one step closer to a more normal, healthy skin color.

At hours 3, 6, 9, and 12 on Day 29 of clinical trials, results were seen in 12% to 18% of patients using RHOFADE® cream vs 5% to 9% using vehicle. The most common side effects at the application site include: dermatitis, worsening of rosacea pimples, itching, redness, and pain. These are not all the possible side effects of RHOFADE® cream. Individual results may vary.

LEARN MORE

Learn about what RHOFADE® cream could
 do for you

RHOFADE® cream results

Persistent facial redness in adults due to rosacea is different for everyone. Explore some before and after pictures to see the results of adult patients who were in the clinical trials.

At hours 3, 6, 9, and 12 on Day 29 of clinical trials, results were seen in 12% to 18% of patients using RHOFADE® cream vs 5% to 9% using vehicle. The most common side effects at the application site include: dermatitis, worsening of rosacea pimples, itching, redness, and pain. These are not all the possible side effects of RHOFADE® cream. Individual results may vary.

SEE PATIENT RESULTS

RHOFADE® cream Results

Unretouched photos of clinical trial patient. Individual results may vary.

BASELINE
(DAY 1: BEFORE FIRST DOSE)
AFTER
(DAY 29: HOUR 12)

How RHOFADE® cream works



RHOFADE® cream is a prescription medicine used on the skin (topical) that is applied every day to tighten specific blood vessels near the surface of your skin to visibly help reduce persistent facial redness in adults.

RHOFADE® cream is not a cure for rosacea, and you should still avoid common triggers that are known to aggravate your condition.

Once-a-day, everyday dosing

Apply a pea-sized amount once a day—every day—in a thin layer to cover the entire face (forehead, nose, each cheek, and chin), avoiding the eyes and lips.

  • Wash hands immediately after application

  • Do not use in eyes, mouth, or vagina. Only for use on skin

  • Continue to avoid common triggers

  • Keep out of reach of children

  • Do not apply to irritated skin or open wounds

  • Get medical help right away if you, a child, or anyone else swallows RHOFADE® cream

Not an actual patient

Help take the next step with
 RHOFADE® cream

RHOFADE® cream side effects

In clinical trials, the most common side effects of RHOFADE® cream were application-site reactions of: skin reactions (dermatitis), worsening of rosacea pimples, itching, redness, and pain. These are not all the possible side effects of RHOFADE® cream. Talk to your doctor about any side effects you may experience.

INDICATIONS AND USAGE

RHOFADE® (oxymetazoline hydrochloride, 1%) cream is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

WARNINGS AND PRECAUTIONS

  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use with caution in patients with cerebral or coronary insufficiency, Raynaud's phenomenon, thromboangiitis obliterans, scleroderma, or Sjögren's syndrome and advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 1%) are application site dermatitis, worsening inflammatory lesions of rosacea, application site pruritis, application site erythema, and application site pain.

MEDICAL INFORMATION and ADVERSE DRUG EVENTS REPORTING

To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 1-844-825-8500 or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

For more information, please see full Prescribing Information and Patient Information Leaflet.